$71.83+0.61 (+0.86%)
U.S.
U.S. Physical Therapy, Inc. in the Healthcare sector is trading at $71.83. The stock is currently near its 52-week low of $66.67, remaining 10.1% below its 200-day moving average. Technical signals show oversold RSI of 20 and bearish MACD signal, explaining why USPH maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
U.S. Physical Therapy, Inc., together with its subsidiaries, operates and manages outpatient physical therapy clinics. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company provides pre-a...
PACS Group Inc. (NYSE:PACS) is one of the best up and coming stocks with highest upside potential. On April 27, PACS Group appointed Carey P. Hendrickson as its Chief Financial Officer. Hendrickson, a seasoned financial leader with nearly 40 years of experience, succeeds co-founder Mark Hancock, who had served as interim CFO since September 2025. […]
Is USPH a good stock to buy? We came across a bullish thesis on U.S. Physical Therapy, Inc. on Quality At A Fair Price’s Substack. In this article, we will summarize the bulls’ thesis on USPH. U.S. Physical Therapy, Inc.’s share was trading at $75.72 as of April 20th. USPH’s trailing and forward P/E were 53.32 and 27.03, respectively, according to Yahoo […]
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Quest Diagnostics (DGX) delivered earnings and revenue surprises of +5.45% and +3.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
On April 14, 2026, U.S. Physical Therapy, Inc. entered into a Fourth Amended and Restated Credit Agreement providing US$450,000,000 in senior credit facilities, including a US$275,000,000 revolving line and a US$175,000,000 term loan maturing in 2031. The expanded access to long-term credit, earmarked for refinancing existing borrowings and funding acquisitions and growth initiatives, reshapes the company’s financial flexibility and capacity to pursue its clinic and employer-health expansion...